Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High-Intensity Statin Therapy After Stroke

Stroke; ePub 2017 Sep 15; Kim, et al

High-intensity statin therapy with good adherence was significantly associated with a lower risk of adverse events after acute ischemic stroke, a recent study found. The retrospective cohort included 8,001 patients admitted with acute ischemic stroke between 2002 and 2012. Statin adherence and intensity were determined for a period of 1 year after the index stroke. The primary outcome was a composite of recurrent stroke, myocardial infarction, and all-cause mortality. Researchers found:

  • 2,284 patients developed a primary outcome during the mean follow-up period of 4.69±2.72 years.
  • Compared with patients with no statin, adjusted hazard ratios were 0.74 for good adherence, 0.93 for intermediate adherence, and 1.07 for poor adherence to statin.
  • Among the 1,712 patients with good adherence, risk of adverse events was lower in patients with high-intensity statin (aHR, 0.48), compared with those with low-intensity statin.
Citation:

Kim J, Lee HS, Nam CM, Heo JH. Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke. [Published online ahead of print September 15, 2017]. Stroke. doi:10.1161/STROKEAHA.117.018140.

This Week's Must Reads

LDL-C Reduction with Evolocumab & PCSK9 Inhibitors, J Am Heart Assoc; ePub 2017 Oct 2; Toth, et al

Efficacy of Evolocumab in Patients with HeFH, J Clin Lipidol; ePub 2017 Sep 22; Hovingh, et al

Patient Access to PCSK9 Inhibitor Therapy, JAMA Cardiol; ePub 2017 Sep 27; Navar, et al

LDL Pattern & Mortality After Myocardial Infarction, J Clin Lipidol; ePub 2017 Oct 3; Pokharel, et al

Increased Risk of HF and AF in Patients With FH, Atherosclerosis; 2017 Nov; Hovland, Mundal, et al

Must Reads in Hypercholesterolemia

LDL-C Reduction with Evolocumab & PCSK9 Inhibitors, J Am Heart Assoc; ePub 2017 Oct 2; Toth, et al

Efficacy of Evolocumab in Patients with HeFH, J Clin Lipidol; ePub 2017 Sep 22; Hovingh, et al

Patient Access to PCSK9 Inhibitor Therapy, JAMA Cardiol; ePub 2017 Sep 27; Navar, et al

LDL Pattern & Mortality After Myocardial Infarction, J Clin Lipidol; ePub 2017 Oct 3; Pokharel, et al

Increased Risk of HF and AF in Patients With FH, Atherosclerosis; 2017 Nov; Hovland, Mundal, et al